CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Agilux Laboratories for $64.9 million in cash, a transaction completed in September 2016, structured as all cash.
Agilux Laboratories operates in Discovery and Safety Assessment (DSA), is based in United States. Agilux was a CRO that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic (DMPK) services, and pharmacology services.
The acquisition supports our strategy to offer clients a broader, integrated portfolio that provides services continuously from the earliest stages of drug research through the nonclinical development process. The purchase price for Agilux was $64.9 million in cash.
DSA segment, discovery / DMPK services
In September, we acquired Agilux, a CRO that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic services, and pharmacology services. The purchase price for Agilux was $64.9 million in cash.Charles River FY2016 10-K, Business Acquisitions note
Advisory firms were not disclosed for this transaction.